CoLucid was founded by Pappas Ventures and is developing oral Lasmiditan for the acute treatment of migraine headache and intravenous Lasmiditan for treatment of headache pain by health care professionals. CoLucid is partnered with ILDONG Pharmaceutical Co, Ltd, under a distribution and supply agreement for Lasmiditan, in South Korea and Southeast Asia.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/13/15 | $37,100,000 | Series C |
Auriga Partners Domain Associates Novo Ventures Pappas Ventures Pearl Street Venture Funds Triathlon Medical Ventures | undisclosed |
